Evidence map›Paper›PMID 25449024›Full record

ArticleGastroenterology2014

FDA perspective on sofosbuvir therapy for patients with chronic hepatitis C virus genotype 1 infection who did not respond to treatment with pegylated interferon and ribavirin.

Poonam Mishra, Jeffry Florian, Karen Qi, Wen Zeng, Lisa K Naeger, Eric Donaldson, Sarah Connelly, Jules O'Rear, Dionne Price, Jeffrey Murray and 1 more

Abstract readComment
PubMed Publisher
In one paragraph

Article in Gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. KASL clinical practice guidelines: management of hepatitis C.Clinical and molecular hepatology · 2016
    Guideline
  2. [Guidelines for the prevention and treatment of hepatitis C (2019 version)].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2019
    Article
  3. Review
  4. [The guideline of prevention and treatment for hepatitis C: a 2015 update].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2015
    Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Poonam MishraUS Food and Drug Administration, Silver Spring, Maryland.
Jeffry FlorianUS Food and Drug Administration, Silver Spring, Maryland.
Karen QiUS Food and Drug Administration, Silver Spring, Maryland.
Wen ZengUS Food and Drug Administration, Silver Spring, Maryland.
Lisa K NaegerUS Food and Drug Administration, Silver Spring, Maryland.
Eric DonaldsonUS Food and Drug Administration, Silver Spring, Maryland.
Sarah ConnellyUS Food and Drug Administration, Silver Spring, Maryland.
Jules O'RearUS Food and Drug Administration, Silver Spring, Maryland.
Dionne PriceUS Food and Drug Administration, Silver Spring, Maryland.
Jeffrey MurrayUS Food and Drug Administration, Silver Spring, Maryland.
Debra BirnkrantUS Food and Drug Administration, Silver Spring, Maryland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Drug ApprovalAntiviral AgentsHepatitis C, ChronicHumansSofosbuvirUridine MonophosphateAntiviral AgentsSofosbuvirUridine Monophosphate

Identifiers

PMID25449024

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.